Biocryst Pharmaceuticals (BCRX) EBT Margin Growth (5y) (2015 - 2026)
Powered by 
Analysis
Biocryst Pharmaceuticals (BCRX) EBT Margin Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.56 Bn | 197.57 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.34 Bn | 178.16 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.22 Bn | 124.37 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.55 Bn | 56.37 Bn | 1.37 Bn |
| 6 | Moderna | 54.32 Bn | 49.19 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.32 Bn | 31.01 Bn | 992.69 Mn |
| 8 | Biogen | 31.24 Bn | 29.95 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.17 Bn | 30.17 Bn | 1.16 Mn |
| 10 | Biocryst Pharmaceuticals | 2.31 Bn | 1.95 Bn | 214.41 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12,288.00 |
| Mar 31, 2026 | -12,355.00 |
| Dec 31, 2025 | 3.65 Mn |
| Sep 30, 2025 | 76,315.00 |
| Jun 30, 2025 | 135,089.00 |
| Mar 31, 2025 | 77,968.00 |
| Dec 31, 2024 | -1,269.00 |
| Sep 30, 2024 | 211,471.00 |
| Jun 30, 2024 | 257,185.00 |
| Mar 31, 2024 | 49,665.00 |
| Dec 31, 2023 | 92,138.00 |
| Sep 30, 2023 | 203,766.00 |
| Jun 30, 2023 | 6,928.00 |
| Mar 31, 2023 | 52,637.00 |
| Dec 31, 2022 | 41,437.00 |
| Sep 30, 2022 | 12,018.00 |
| Jun 30, 2022 | 47,319.00 |
| Mar 31, 2022 | -1,374.00 |
| Dec 31, 2021 | 8,086.00 |
| Sep 30, 2021 | -693.00 |